arrow
O

Oghenekome Gbinigie

university of oxford
H指数:22
被引数:2,172

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

伊维菌素用于社区成人新型冠状病毒肺炎 (原则): 一项开放、随机、对照、适应性的短期和长期结果平台试验

2024-04-015
OAAI
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

molnupiravir在高危成人门诊患者中SARS-CoV-2病毒和抗体反应的随机对照试验

2024-02-2310
OAAI
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial

莫那比拉韦对高危社区新型冠状病毒肺炎成人的成本效用分析: 全景试验的经济评估

2024-01-162
OAAI
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
LANCET
IF88.5
2023-01-01237
OAAI
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
2022-03-2328
OAAI
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
2021-09-0155
OAAI
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
LANCET
IF88.5
2021-09-01157
OAAI
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
LANCET
IF88.5
2021-03-01190
OAAI